Primary Biliary Cholangitis Global Market Report 2024

Description

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive inflammation and destruction of the small bile ducts within the liver. This condition can lead to impaired bile flow, liver damage, and various related complications. PBC primarily affects middle-aged women and is often associated with symptoms such as fatigue, itching, and abdominal discomfort.

The main types of treatment for primary biliary cholangitis are drugs and liver transplantation. A drug is any chemical substance that causes a change in an organism's physiology or psychology when consumed, and ursodeoxycholic acid (UDCA) is the standard first-line treatment for PBC. UDCA helps improve liver function, reduce liver inflammation, and slow down disease progression. Primary biliary cholangitis is diagnosed through various imaging tests such as magnetic resonance elastography (MRE), magnetic resonance cholangiopancreatography (MRCP), ultrasound, fibroscan, as well as blood tests including cholesterol tests, antibody tests, and liver function tests. These diagnostic methods are employed by end-users such as specialty clinics, homecare services, and other healthcare facilities.

The primary biliary cholangitis market research report is one of a series of new reports from The Business Research Company that provides primary biliary cholangitis market statistics, including primary biliary cholangitis industry global market size, regional shares, competitors with a primary biliary cholangitis market share, detailed primary biliary cholangitis market segments, market trends and opportunities, and any further data you may need to thrive in the primary biliary cholangitis industry. This primary biliary cholangitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The primary biliary cholangitis market size has grown rapidly in recent years. It will grow from $0.87 billion in 2023 to $0.98 billion in 2024 at a compound annual growth rate (CAGR) of 12.1%. The growth observed in the historical period can be attributed to various factors, including increased disease awareness, a rise in global healthcare expenditure, strategic collaborations in the healthcare sector, a focus on patient advocacy, and government initiatives for liver health. These factors have collectively contributed to the growth and development of approaches for addressing primary biliary cholangitis (PBC) during the historic period.

The primary biliary cholangitis market size is expected to see rapid growth in the next few years. It will grow to $1.46 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The anticipated growth during the forecast period is linked to the expansion of biomarker research, worldwide initiatives in managing rare diseases, heightened collaboration in clinical trials, patient-centric healthcare strategies, and an increased demand for liver transplants. Key trends expected in the forecast period encompass progress in biomarker research, an escalating emphasis on non-invasive diagnostic approaches, research concentration on immunomodulatory therapies, the incorporation of artificial intelligence (AI), the inclusion of patient-reported outcomes in clinical trials, the utilization of telemedicine for patient management, a focus on combination therapies, and the emergence of therapies targeting fibrosis.

The anticipated rise in smoking is poised to drive the expansion of the primary biliary cholangitis market in the coming years. Smoking involves the inhalation and exhalation of smoke generated by burning tobacco or other substances. It is a recognized risk factor for liver diseases, including PBC, and elevated smoking rates may result in an increased number of individuals seeking medical attention for liver-related issues. As an illustration, in July 2023, Statistics Canada reported a 2.2% increase in cigarette production compared to June 2023, with a corresponding 2.6% rise in cigarette sales, reaching 1.4 billion units in June compared to May. Consequently, the upswing in smoking is expected to propel the primary biliary cholangitis market's growth.

The upsurge in liver cancer is anticipated to foster the growth of the primary biliary cholangitis market in the foreseeable future. Liver cancer, a type of cancer originating in the liver cells, holds significance in the context of primary biliary cholangitis due to the heightened risk of various malignancies, including cholangiocarcinoma and hepatocellular carcinoma. The increasing prevalence of the disease and its potential complications contribute to the expansion of the primary biliary cholangitis market. For instance, in October 2022, the National Center for Biotechnology Information reported a projected 55.0% increase in the incidence of liver cancer and a 56.4% rise in the number of deaths between 2020 and 2040. Hence, the surge in liver cancer is a driving force behind the growth of the primary biliary cholangitis market.

The anticipated shortage of skilled healthcare professionals is poised to impede the growth of the primary biliary cholangitis market in the future. The scarcity of qualified healthcare professionals results in delayed diagnosis and treatment, hindering the effective management and monitoring of PBC patients. Moreover, the shortage of skilled healthcare professionals acts as a bottleneck in the progress towards discovering new and more effective therapies for PBC. As an example, in June 2022, the World Health Organization reported a global healthcare workforce shortage of 15 million in 2022. Consequently, the insufficiency of skilled healthcare professionals is a limiting factor in the growth of the primary biliary cholangitis market.

Major companies operating in the primary biliary cholangitis market are directing their efforts towards the development of innovative and specialized treatments. This includes the creation of orphan drugs featuring a combination of obeticholic acid (OCA) and bezafibrates for the treatment of primary biliary cholangitis (PBC), aiming to secure market exclusivity. The combination of OCA and bezafibrate, with an orphan drug designation, seeks to provide a more comprehensive and effective approach to managing PBC treatment, potentially enhancing the quality of life for individuals affected by this rare condition. For example, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, obtained orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate as a potential treatment for PBC, a progressive liver disease, with OCA already approved for PBC in the US.

In March 2023, Ipsen SA, a France-based pharmaceutical company, completed the acquisition of Albireo Pharma, Inc. for an undisclosed amount. This strategic move by Ipsen aims to broaden its rare disease portfolio by incorporating novel pipeline prospects, promising therapies for rare cholestatic liver diseases in both children and adults, and leveraging strong scientific and commercial capabilities. Albireo Pharma Inc., a US-based biopharmaceutical company, is actively developing A3907 therapy for primary biliary cholangitis (PBC), contributing to Ipsen's expansion in the rare disease segment.

Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc, TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.

North America was the largest region in the primary biliary cholangitis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the primary biliary cholangitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary biliary cholangitis market includes revenues earned by entities by providing services such as psychosocial support services, nutritional guidance services, medical diagnosis, and specialized medical care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary biliary cholangitis market also includes sales of products such as fat-soluble vitamins, anti-itch medications, and imaging equipment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Biliary Cholangitis Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on primary biliary cholangitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary biliary cholangitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary biliary cholangitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Treatment Type: Drugs; Liver Transplantation
2) By Diagnosis: Imaging Tests; Magnetic Resonance Elastography (MRE); Magnetic Resonance Cholangiopancreatography (MRCP); Ultrasound; Fibroscan; Blood Tests; Cholesterol Test; Antibody Tests; Liver Tests; Other Diagnoses
3) By End-Users: Specialty Clinics; Homecare; Other End-Users
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck And Co. Inc.; Novartis AG; Bristol-Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r16316

1. Executive Summary

2. Primary Biliary Cholangitis Market Characteristics

3. Primary Biliary Cholangitis Market Trends And Strategies

4. Primary Biliary Cholangitis Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Primary Biliary Cholangitis Market Size and Growth

5.1. Global Primary Biliary Cholangitis Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Primary Biliary Cholangitis Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Primary Biliary Cholangitis Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Primary Biliary Cholangitis Market Segmentation

6.1. Global Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Drugs
Liver Transplantation
6.2. Global Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Imaging Tests
Magnetic Resonance Elastography (MRE)
Magnetic Resonance Cholangiopancreatography (MRCP)
Ultrasound
Fibroscan
Blood Tests
Cholesterol Test
Antibody Tests
Liver Tests
Other Diagnoses
6.3. Global Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Specialty Clinics
Homecare
Other End-Users

7. Primary Biliary Cholangitis Market Regional And Country Analysis

7.1. Global Primary Biliary Cholangitis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Primary Biliary Cholangitis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Primary Biliary Cholangitis Market

8.1. Asia-Pacific Primary Biliary Cholangitis Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Primary Biliary Cholangitis Market

9.1. China Primary Biliary Cholangitis Market Overview
9.2. China Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Primary Biliary Cholangitis Market

10.1. India Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Primary Biliary Cholangitis Market

11.1. Japan Primary Biliary Cholangitis Market Overview
11.2. Japan Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Primary Biliary Cholangitis Market

12.1. Australia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Primary Biliary Cholangitis Market

13.1. Indonesia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Primary Biliary Cholangitis Market

14.1. South Korea Primary Biliary Cholangitis Market Overview
14.2. South Korea Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Primary Biliary Cholangitis Market

15.1. Western Europe Primary Biliary Cholangitis Market Overview
15.2. Western Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Primary Biliary Cholangitis Market

16.1. UK Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Primary Biliary Cholangitis Market

17.1. Germany Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Primary Biliary Cholangitis Market

18.1. France Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Primary Biliary Cholangitis Market

19.1. Italy Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Primary Biliary Cholangitis Market

20.1. Spain Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Primary Biliary Cholangitis Market

21.1. Eastern Europe Primary Biliary Cholangitis Market Overview
21.2. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Primary Biliary Cholangitis Market

22.1. Russia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Primary Biliary Cholangitis Market

23.1. North America Primary Biliary Cholangitis Market Overview
23.2. North America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Primary Biliary Cholangitis Market

24.1. USA Primary Biliary Cholangitis Market Overview
24.2. USA Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Primary Biliary Cholangitis Market

25.1. Canada Primary Biliary Cholangitis Market Overview
25.2. Canada Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Primary Biliary Cholangitis Market

26.1. South America Primary Biliary Cholangitis Market Overview
26.2. South America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Primary Biliary Cholangitis Market

27.1. Brazil Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Primary Biliary Cholangitis Market

28.1. Middle East Primary Biliary Cholangitis Market Overview
28.2. Middle East Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Primary Biliary Cholangitis Market

29.1. Africa Primary Biliary Cholangitis Market Overview
29.2. Africa Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Primary Biliary Cholangitis Market Competitive Landscape And Company Profiles

30.1. Primary Biliary Cholangitis Market Competitive Landscape
30.2. Primary Biliary Cholangitis Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche Ltd.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Merck And Co. Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Novartis AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Bristol-Myers Squibb Company
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Primary Biliary Cholangitis Market Other Major And Innovative Companies

31.1. AstraZeneca plc
31.2. GlaxoSmithKline plc
31.3. Takeda Pharmaceutical Company
31.4. Amgen Inc.
31.5. Boehringer Ingelheim International GmbH.
31.6. Gilead Sciences Inc.
31.7. Vertex Pharmaceuticals
31.8. Dr. Reddy's Laboratories Ltd.
31.9. Amneal Pharmaceuticals LLC
31.10. Alnylam Pharmaceuticals Inc.
31.11. Ionis Pharmaceuticals Inc.
31.12. Intercept Pharmaceuticals Inc
31.13. Arrowhead Pharmaceuticals Inc.
31.14. CureVac N.V.
31.15. Sangamo Therapeutics Inc.

32. Global Primary Biliary Cholangitis Market Competitive Benchmarking

33. Global Primary Biliary Cholangitis Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Primary Biliary Cholangitis Market

35. Primary Biliary Cholangitis Market Future Outlook and Potential Analysis

35.1 Primary Biliary Cholangitis Market In 2028 - Countries Offering Most New Opportunities
35.2 Primary Biliary Cholangitis Market In 2028 - Segments Offering Most New Opportunities
35.3 Primary Biliary Cholangitis Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer